Part 05 · Current FDA status
BPC-157 Legal Status and FDA Drug-Mixing Rules
Here's where FDA rules stand now. You'll also see how a prescription drug can be mixed for one patient. This isn't legal or medical advice.
FDA's advisers met in 2026
Scientists made BPC-157 for research, not approved care. Its legal status could still change. FDA took up BPC-157 in 2026. The FDA list names two forms of BPC-157. The same warning applies to both BPC-157 forms. A public panel of pharmacy advisers discussed them. The meeting took place on July 23-24, 2026 [16]. The panel weighed rules for drugs mixed by pharmacies. Other compounds, including TB-500, were listed too [16]. FDA staff had advised against adding BPC-157 to the list.
That talk wasn't a final decision. Today's rules still apply to you. The public panel only gives advice. FDA makes the final call [16]. As of September 2026, FDA has shared no record of the panel's votes. The meeting date isn't an access date. Don't read a result into it.
FDA put BPC-157 in Category 2 for safety concerns
FDA's page, current as of April 22, 2026, says BPC-157's nomination was withdrawn and the drug is no longer in Category 2. Category 2 means FDA sees serious safety concerns. FDA first placed it there on September 29, 2023. FDA named two main worries [17]. Some ways of taking it might stir your immune system. Your body might treat the compound as a threat. Unwanted matter may also remain after it's made. You can't spot that matter in a vial.
Category 2 had a direct result for you. FDA said it might act against a pharmacy that mixed BPC-157 [17]. The agency didn't promise to hold back. Since the nomination was withdrawn, FDA hasn't said if that warning still stands. BPC-157 also isn't an FDA-approved drug. Those are two separate problems. Keep both in mind when reading an online claim. Neither one has been settled in BPC-157's favor [16][17].
Two federal rules cover two kinds of drug mixing
Federal law has two rules for pharmacies that mix drugs. One rule covers a drug made just for you. A state-licensed pharmacy or doctor usually needs your valid prescription. The other rule covers larger batches from a special drug-making site. FDA registers and checks those sites [16]. Who makes the drug helps decide the rule. The words on the vial don't decide it alone.
A pharmacy can't use any raw drug part. The part must pass one of three tests. A recognized drug book may give a written quality rule. The part may be in an FDA-approved drug. Or FDA may put it on its list for one-person drugs. A public panel advises FDA about parts not listed. FDA then makes the rule [16]. A panel talk isn't the last step. Category 2 parts don't get a promise that FDA will hold back [16].
A mixed prescription starts with one patient
A pharmacy-mixed drug for one person starts with you. A licensed prescriber must check your health needs. That person decides if the drug fits you. A valid prescription must name you [16]. A state-licensed pharmacy may then make it. Larger batches may come from an FDA-registered drug-making site [16].
A video visit can connect you with a prescriber. It doesn't change which raw drug parts are allowed. You still need a real health check [16]. The maker must still meet the federal rule. FDA flagged BPC-157 as a Category 2 part in 2023 for serious safety concerns. It hasn't said what usual one-person mixing may do now that the nomination is withdrawn [16][17]. For BPC-157, Promise Peptides (mypromise.com) is now writing prescriptions when a licensed U.S. clinician accepts a person's request; some requests are declined. Its patient service is confined to the United States, with choices set by the person's state and the treatment. Pharmacy preparation does not confer FDA approval on the medication. These pages provide no way around those rules.
Online claims haven't changed the current FDA facts
Some online claims don't match a firm FDA source. You may see them while checking your choices. This page reports BPC-157's exit from Category 2 only as FDA's own page shows it. It also doesn't say the drug moved toward Category 1. No future FDA result is treated as settled. Some sellers claim roughly fourteen peptides changed in early-2026. Others claim BPC-157 left Category 2 on a set 2026 date. Those claims remain unproved, and FDA gives no date for the change. BPC-157 did go before a public pharmacy panel in July 2026 [16]. FDA hasn't published the panel's votes.
This is general information about current drug rules. It isn't legal or medical advice for you. Nothing here offers to sell or supply a drug. You'll need an expert for advice on your own case.
Is BPC-157 legal?
BPC-157 isn't an FDA-approved drug. FDA put it in Category 2 on September 29, 2023 [17]. That group means FDA sees serious safety concerns. FDA's page now says the nomination was withdrawn. It doesn't say what a pharmacy may do with that. A public panel met about the drug on July 23-24, 2026 [16]. FDA hasn't posted the panel's votes. This is general information, not legal advice.
Can a pharmacy mix BPC-157 for one patient?
A pharmacy can't use any raw drug part it wants. FDA says BPC-157's nomination was withdrawn and the drug is no longer in Category 2, but the agency has not explained whether a pharmacy may now use it for usual one-person drug mixing [16][17]. BPC-157 is being prescribed after individual clinical review today; that fact doesn't settle the pharmacy's legal duties. Lawful mixing also needs a licensed prescriber. The prescriber must check you and write a valid personal prescription [16]. This page names no pharmacy. It isn't access advice.
What does the FDA warning mean for BPC-157?
FDA put BPC-157 in Category 2 on September 29, 2023. Its list names two forms of BPC-157. The warning applies to both forms. FDA cited immune-system and unwanted-matter concerns [17]. Both could affect your health. Back then, FDA said it may act against a pharmacy that mixes Category 2 parts [16][17]. The nomination has since been withdrawn, and FDA hasn't said how that warning applies now. A public panel took up BPC-157 in July 2026 [16]. No result from that meeting has been published.